Michael H. Davidson - 06 Jan 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Executive Officer, Director
Signature
/s/ Michael H. Davidson
Issuer symbol
NAMS
Transactions as of
06 Jan 2025
Transactions value $
$0
Form type
4
Filing time
07 Jan 2025, 17:21:22 UTC
Previous filing
02 Jan 2025
Next filing
28 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Award +124K 124K 07 Jan 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +670K $0.00 670K 06 Jan 2025 Ordinary Shares 670K $25.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represenets restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
F2 Each RSU was granted on January 7, 2025 for no consideration.
F3 25% of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.